Preclinical Focus, Clinical Mindset

At LIDE Biotech, we believe the path to successful drug development starts well before the clinic, in preclinical models that mirror real-world biology.

Founded in 2011 by overseas returnees, LIDE’s founding vision is rooted in a translational mindset, leveraging tools that bring preclinical studies as close as possible to clinical relevance.

  • High-quality, patient-derived xenograft (PDX) mouse models, developed in-house, derived from our direct relationships with 100+ hospitals all over China.
  • Faster in-vivo alternatives like MiniPDX or IO-FIVE, to inform program decisions earlier and with more confidence.

Primarily a domestic China focused company until 2022, LIDE has spent the last few years focused on bringing our expertise overseas, expanding our presence to empower more scientists, accelerate more breakthroughs, and help move promising treatments one step closer to patients in need.

Whether in San Francisco, Stockholm or Shanghai, our promise is the same: a robust preclinical platform delivering clinically relevant results.

Connect with us to stay up to date on the latest news and innovations:

LinkedIn

WeChat

YouTube